Latest Clinical Partnerships News

4DMedical secures a key clinical adoption milestone as the University of Miami begins using its CT – VQ™ respiratory imaging technology, following Stanford’s lead. Meanwhile, Lahey Hospital inks a two-year deal for IQ-UIP™, underscoring growing traction in US academic medical centers.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

dorsaVi reports a striking 15-fold increase in US Physical Therapy clinic subscriptions for its ViMove+ product, driven by strong surgeon endorsements and a successful face-to-face training rollout.

Micro-X Ltd has secured a $4.4 million Australian Government grant to develop and trial a portable Head CT scanner designed for standard ambulances, aiming to transform emergency stroke care with faster diagnosis and treatment.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.

dorsaVi’s Q3 FY25 report reveals growing adoption of its AI-powered video movement analysis in the US, a new elite athlete research partnership, and the launch of a pioneering 3D ACL injury prevention test.